Literature DB >> 3549395

Appropriate age for measles vaccination in the United States.

W A Orenstein, L Markowitz, S R Preblud, A R Hinman, A Tomasi, K J Bart.   

Abstract

The appropriate age for measles vaccination is determined by weighing the risk of measles disease and complications at a given age with vaccine efficacy at that age. In the United States, measles vaccine was initially used in children as young as 9 months of age because the disease was common and complications were greatest in persons less than 1 year of age. In 1965, when it became apparent that vaccine failure was unacceptably high in children less than 1 year and when epidemiologic analysis indicated that children greater than or equal to 1 year, particularly schoolchildren, were the primary focus of measles transmission, the vaccination age was raised to 12 months. In 1976, further studies showed efficacy was slightly higher at 15 months of age versus 12 months or 12-14 months of age. Because the risk of acquiring measles in children less than 15 months was low, the age for routine vaccination was increased to 15 months. This age recommendation may be appropriate for developed countries where the epidemiology of measles may be similar to the epidemiology in the United States. However, this age is inappropriate for many countries in the developing world where the risks of measles and complications from measles are high in young preschool children. In those countries, the recommended age for routine vaccination against measles is generally 9 months.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3549395

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  25 in total

Review 1.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 2.  Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.

Authors:  Stephen J Russell; Dusica Babovic-Vuksanovic; Alice Bexon; Roberto Cattaneo; David Dingli; Angela Dispenzieri; David R Deyle; Mark J Federspiel; Adele Fielding; Eva Galanis; Martha Q Lacy; Bradley C Leibovich; Minetta C Liu; Miguel Muñoz-Alía; Tanner C Miest; Julian R Molina; Sabine Mueller; Scott H Okuno; Nandakumar Packiriswamy; Tobias Peikert; Corey Raffel; Frits Van Rhee; Guy Ungerechts; Paul R Young; Yumei Zhou; Kah-Whye Peng
Journal:  Mayo Clin Proc       Date:  2019-06-22       Impact factor: 7.616

3.  A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy.

Authors:  S E Robertson; L E Markowitz; D A Berry; E F Dini; W A Orenstein
Journal:  Public Health Rep       Date:  1992 Jan-Feb       Impact factor: 2.792

4.  Statement on recommended use of measles vaccine in Canada.

Authors: 
Journal:  CMAJ       Date:  1990-08-15       Impact factor: 8.262

5.  A measles outbreak at a college with a prematriculation immunization requirement.

Authors:  B S Hersh; L E Markowitz; R E Hoffman; D R Hoff; M J Doran; J C Fleishman; S R Preblud; W A Orenstein
Journal:  Am J Public Health       Date:  1991-03       Impact factor: 9.308

6.  A model for estimating the impact of changes in children's vaccines.

Authors:  K N Simpson; A K Biddle; N R Rabinovich
Journal:  Am J Public Health       Date:  1995-12       Impact factor: 9.308

7.  Outbreak of measles in a highly vaccinated secondary school population.

Authors:  P A Sutcliffe; E Rea
Journal:  CMAJ       Date:  1996-11-15       Impact factor: 8.262

Review 8.  Effectiveness of measles vaccination and vitamin A treatment.

Authors:  Christopher R Sudfeld; Ann Marie Navar; Neal A Halsey
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

9.  MMR Vaccine: When Is the Right Time for the Second Dose?

Authors:  Oscar R Herrera; Terrika A Thornton; Richard A Helms; Stephan L Foster
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

10.  Using Disease Epidemiology to Optimize Immunization Schedules.

Authors:  Cindy M Weinbaum; Walter A Orenstein
Journal:  JAMA Pediatr       Date:  2017-10-01       Impact factor: 16.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.